Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021. Journal of the National Comprehensive Cancer Network : JNCCN von Mehren, M., Kane, J. M., Bui, M. M., Choy, E., Connelly, M., Dry, S., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Homsi, J., Keedy, V., Kelly, C. M., Kim, E., Liebner, D., McCarter, M., McGarry, S. V., Meyer, C., Pappo, A. S., Parkes, A. M., Paz, I. B., Petersen, I. A., Poppe, M., Riedel, R. F., Rubin, B., Schuetze, S., Shabason, J., Sicklick, J. K., Spraker, M. B., Zimel, M., Bergman, M. A., George, G. V. 2020; 18 (12): 1604–12

Abstract

The NCCN Guidelines for Soft Tissue Sarcoma provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with soft tissue sarcomas. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including the development of a separate and distinct guideline for gastrointestinal stromal tumors (GISTs); reconception of the management of desmoid tumors; inclusion of further recommendations for the diagnosis and management of extremity/body wall, head/neck sarcomas, and retroperitoneal sarcomas; modification and addition of systemic therapy regimens for sarcoma subtypes; and revision of the principles of radiation therapy for soft tissue sarcomas.

View details for DOI 10.6004/jnccn.2020.0058

View details for PubMedID 33285515